secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2023-03-17T23:59:59+00:00
Accession:  0001628280-23-008516
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo announces termination of Novartis and Biogen collaborations; loses milestone/royalty potential
--------------------------------------------------------------------------------

- Novartis terminated collaboration (effective June 11, 2023); Sangamo loses up to $720M in milestones and royalties.
- Biogen terminated collaboration (effective June 15, 2023); Sangamo loses up to $2.37B in milestones and royalties.
- Sangamo will explore internal development or new partners for CNS programs but faces uncertainty.
- Company expects existing cash runway of at least 12 months from Dec. 31, 2022 remains adequate despite terminations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000162828023008516/0001628280-23-008516-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000162828023008516/sgmo-20230313.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-008516

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer